Skip directly to content

January 10, 2018 – The Tuberculosis Trials Consortium (TBTC) is a global leader in research and development for better tools to prevent, diagnose, and treat tuberculosis (TB). Housed within the U.S. Centers for Disease Control and Prevention (CDC), the TBTC conducts clinical research of high public health relevance and is key to strengthening domestic and global campaigns to eliminate TB. TBTC studies have produced several notable breakthroughs, including a shorter regimen for preventing TB (3HP) using isoniazid and rifapentine. The Community Research Advisors Group (CRAG) produced this

January 5, 2018 – In advance of a U.S. Senate Committee on Finance hearing on January 9, 2018, TAG and over 60 other civil society organizations issued a statement asking U.S. senators to oppose the confirmation of Alex Azar as Secretary of Health and Human Services, citing Azar's industry track-record and stances that counter public health and racial, gender, and economic justice. While Azar was president of Lilly USA, insulin costs nearly tripled.

January 5, 2018 — TAG is seeking to hire a Finance Manager who will report to the Deputy Executive Director – Development and Operations (DED-DO). The Finance Manager will ensure timely and accurate development, management, and reporting of TAG's financials. They will work closely with the DED-DO, Executive Director (ED), Administrator, and Program Directors, and attend Board Finance Committee meetings on a monthly basis or as requested.

The Finance Manager's role requires tact, diplomacy, and interaction with staff and the Board. Strong communications skills, written and verbal, are a must.

TAG Statement on Forbidden Words in Budget Documents

Reports of words being prohibited in the budget plans of agencies under the Department of Health & Human Services (HHS) indicate a horrifying acceleration of the Trump administration’s efforts to undermine science and public health

New York, December 20, 2017 – Treatment Action Group (TAG) joins the chorus of rational voices expressing outrage at reports that HHS agencies have received instructions to avoid words unpalatable to the Trump administration in their budget requests.

While certain officials are now suggesting the prohibitions represent recommendations designed to smooth the budget

Hasty Passage of the Tax and Health Care Bill

Contact:
Suraj Madoori
TAG U.S. and Global Health Policy Director
917-530-5996
smadoori@treatmentactiongroup.org

With the hasty passage of the tax and health care bill passed along party lines yesterday afternoon, Congress has sent a clear message on how they prioritize communities living with and vulnerable to HIV, tuberculosis (TB), and hepatitis C virus (HCV) in the upcoming mid-term election year. The bill was signed on December 22, 2017 by the President, and it hands massive tax-cuts to corporations and the wealthy.

HCV Treatment Access in U.S. Prisons: Legal and Policy Challenges
October 2, 2017 - Treatment Access Group joined oined National Viral Hepatitis Roundtable and the Hepatitis Education Project to present this update on HCV DAA treatment access in the U.S. prison system.

HCV Global Access Webinars Archive
2015 - A series of two Webinars that offered the opportunity to engage with leading experts on cutting-edge issues in HCV treatment access advocacy.

 

Webinar: Hepatitis C Treatment Access in Prisons: Legal and Policy Challenges

On Monday, October 2, 2017, Treatment Access Group joined National Viral Hepatitis Roundtable and the Hepatitis Education Project to present this update on HCV DAA treatment access in the U.S. prison system. The webinar included information about newly available treatments, drug pricing in the prison system, key lawsuits, and legal tactics designed to expand access in correctional settings.

Speakers included:

  • Mandy Altman, MPA
    Correctional Health Program Manager, Hepatitis Education Project
  • Elizabeth Paukstis, MA, JD
    Public Policy Director, NVHR
  • Annette Gaudino
    HCV/HIV Project Co-Director,

Webinar: Exploring the Implications of the Delamanid Phase III and STREAM Trial Results

Note that the following PDFs listed at the top of this page were handouts shared with the Webinar:
--Phase III Clinical Trial Results at the 48th Union World Conference on Lung Health: Implications for the Field1, PDF
--TB CAB's Proposed Development Pathway for Regimens to Treat Extensively Drug-Resistant Tuberculosis, PDF
--The Devil We Know: Is the Use of Injectable Agents for the Treatment of MDR-TB Justified? PDF

               The Results Are In: Now What? Webinar Video

The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results.

On December 13, 2017, TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE). The meeting was held in preparation for the UAE’s Universal Period Review (UPR), a mechanism by which the human rights record of each United Nations member state is reviewed by other countries every five years.  

Civil society organizations can submit information to the HRC and put forward recommendations for how the country under review can better respect its human rights obligations as established by the Universal

On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

Introduction - Erica Lessem (Treatment Action Group) and Eloisa "Louie" Zepeda-Teng (TB meningitis survivor, the Philippines)

 

Remarks - Dr. Lucica Ditiu (Stop TB Partnership)

 

Panel 1: Perceptions of Risk - Dr. Cesar Bonilla (formerly of National TB Program, Perú), Dr.  Aamir Khan (Interactive Research & Development, Pakistan), Dr.

Pages